Crisugabalin Shows Significant Pain Reduction in Postherpetic Neuralgia Patients: Study

To ascertain the efficacy and safety of crisugabalin in treating postherpetic neuralgia, this randomized clinical trial was performed from November 2021 through January 2023 at 48 tertiary care centers in China. It was a two-arm clinical study: first, a double-blind phase for 12 weeks and an open-label extension for 14 weeks. This comprised 366 adult patients with postherpetic neuralgia with an average daily pain score of at least 4 on the Numeric Pain Rating Scale (0-10) over the week preceding study entry. Patients who failed to respond to high doses of pregabalin ≥300 mg/d or gabapentin ≥1200 mg/d were excluded.

Participants were randomly assigned in a 1:1:1 ratio to crisugabalin 40 mg/d (20 mg twice daily), crisugabalin 80 mg/d (40 mg twice daily), or placebo. All participants completed the 2-week screening period, followed by the 7-day run-in phase and then treatment for 12 weeks.

The average daily pain score (ADPS) change from baseline to week 12 was the primary efficacy endpoint. The results were deemed clinically significant reductions in pain for both of the dosage groups taking crisugabalin compared with the placebo group:

• For patients in the 40 mg/d dosage group of crisugabalin, the least squares mean change in ADPS was −2.2 (SD 0.2).

• Least squares mean change in ADPS showed marked decreases in patients taking crisugabalin at 80 mg/d by an even greater amount of −2.6 (SD 0.2).

• Placebo group: mean change in ADPS was −1.1 (SD 0.2).

• LS Mean difference between crisugabalin 40 mg/d and placebo was −1.1 (95% CI, −1.6 to −0.7; P < 0.001), and between crisugabalin 80 mg/d and placebo was −1.5 (95% CI, −2.0 to −1.0; P < 0.001).

No new safety issues emerged during the 12 weeks of double-blind treatment. Side effects were generally similar between treatment groups and placebo. All extensions of the trial in an open-label manner further served to confirm that the drug was safe, since all patients continuing received crisugabalin 40 mg twice daily and no significant safety issues developed.

Overall, crisugabalin at a dose of 40 mg/d or 80 mg/d resulted in statistically significant improvements in pain reduction in patients suffering from postherpetic neuralgia. These results imply that crisugabalin can be one useful new alternative to treating patients diagnosed with postherpetic neuralgia when they look for other options besides traditional calcium channel ligands such as pregabalin or gabapentin.

Reference:

Zhang, D., Lei, T., Qin, L., Li, C., Lin, X., Wang, H., Zhang, G., Zhang, S., Shi, K., Li, L., Yang, Z., Yang, X., Ba, X., Gao, Y., Zhang, Z., Wang, G., Wu, L., Wang, Y., Wang, Y., … Lu, Q. (2024). Efficacy and safety of crisugabalin (HSK16149) in adults with postherpetic neuralgia: A phase 3 randomized clinical trial. JAMA Dermatology (Chicago, Ill.). https://doi.org/10.1001/jamadermatol.2024.3410